Apogee Therapeutics, Inc. Company Profile
Background
Company Overview
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative biologic therapies for the treatment of inflammatory and immunological (I&I) diseases. Founded in 2022 and headquartered in San Francisco, California, the company focuses on addressing unmet needs in conditions such as atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE).
Mission and Vision
Apogee's mission is to reshape the standard of care for individuals living with I&I diseases by developing best-in-class therapies that offer improved efficacy and dosing regimens. The company's vision is to provide patients with treatments that not only address the underlying causes of their conditions but also enhance their quality of life through less frequent dosing and better overall outcomes.
Industry Significance
The biotechnology industry, particularly in the realm of immunology and inflammation, is characterized by rapid advancements and a high demand for novel therapies. Apogee's focus on biologic treatments positions it within a competitive landscape, aiming to introduce therapies that offer differentiated benefits over existing options.
Key Strategic Focus
Core Objectives
Apogee aims to develop differentiated biologic therapies that address the root causes of I&I diseases, providing patients with more effective and convenient treatment options. The company's strategy includes advancing its pipeline of antibody programs and exploring combination therapies to enhance therapeutic efficacy.
Areas of Specialization
The company specializes in the development of monoclonal antibodies targeting key cytokines and receptors involved in inflammatory pathways, such as IL-13, IL-4Rα, OX40L, and TSLP. These targets are central to the pathogenesis of various I&I conditions.
Key Technologies Utilized
Apogee employs advanced antibody engineering techniques, including half-life extension modifications like YTE and LS amino acid substitutions. These modifications are designed to enhance binding to the neonatal Fc receptor (FcRn), reducing lysosomal degradation and thereby prolonging the antibody's presence in circulation.
Primary Markets Targeted
The company's primary markets include the United States, Europe, and Japan, focusing on regions with high prevalence of I&I diseases and significant unmet medical needs.
Financials and Funding
Funding History
Apogee completed an upsized Initial Public Offering (IPO) in July 2023, raising approximately $345 million by selling 20,297,500 shares at $17.00 per share.
Recent Funding Rounds
The IPO was the company's most recent funding round, providing substantial capital to support its clinical development programs.
Notable Investors
Specific details about individual investors are not publicly disclosed.
Utilization of Capital
The funds raised are allocated towards advancing the company's pipeline, including clinical trials for lead candidates APG777 and APG808, as well as expanding research and development efforts to support additional programs.
Pipeline Development
Key Pipeline Candidates
1. APG777: A novel, subcutaneous extended half-life monoclonal antibody targeting IL-13, currently in Phase 2 trials for moderate-to-severe atopic dermatitis.
2. APG808: An extended half-life monoclonal antibody targeting IL-4Rα, with Phase 1 trials initiated ahead of schedule.
3. APG990: A monoclonal antibody targeting OX40L, with Phase 1 trials expected to begin in the third quarter of 2024.
4. APG333: A novel subcutaneous half-life extended anti-TSLP antibody, expected to enter the clinic in 2025.
Stages of Clinical Trials
- APG777: Phase 2 trials for atopic dermatitis, with 16-week proof-of-concept data expected in the second half of 2025.
- APG808: Phase 1 trials, with interim data anticipated in the fourth quarter of 2024.
- APG990: Phase 1 trials, with initiation in healthy volunteers expected in the third quarter of 2024.
- APG333: Preclinical stage, with plans to enter clinical trials in 2025.
Target Conditions
The pipeline targets conditions such as atopic dermatitis, asthma, chronic obstructive pulmonary disease, and eosinophilic esophagitis.
Anticipated Milestones
- APG777: 16-week proof-of-concept data in moderate-to-severe atopic dermatitis expected in the second half of 2025.
- APG808: Interim Phase 1 data in healthy volunteers expected in the fourth quarter of 2024.
- APG990: Phase 1 trial initiation in healthy volunteers expected in the third quarter of 2024.
- APG333: Clinical trial initiation expected in 2025.
Technological Platform and Innovation
Proprietary Technologies
Apogee's proprietary technology focuses on antibody engineering to extend the half-life of biologic therapies, reducing the frequency of dosing required for patients. This approach aims to improve patient adherence and overall treatment outcomes.
Significant Scientific Methods
- YTE and LS Modifications: These amino acid substitutions enhance binding to the neonatal Fc receptor, reducing lysosomal degradation and prolonging antibody circulation.
- Combination Therapies: Apogee is exploring combination treatments, such as APG777 with APG990, to target multiple inflammatory pathways simultaneously, potentially offering broader therapeutic benefits.
Leadership Team
Executive Profiles
- Michael Henderson, M.D.: Chief Executive Officer. Dr. Henderson has extensive experience in drug development and has been instrumental in advancing Apogee's clinical programs.
- Carl Dambkowski, M.D.: Chief Medical Officer. Dr. Dambkowski oversees clinical development and has a background in immunology and clinical research.
- Lisa Bollinger, M.D.: Board Member. Dr. Bollinger brings over 30 years of drug development experience, including regulatory affairs at Merck.
- Matt Batters: General Counsel. Mr. Batters has a background in corporate law and has supported business development activities at Arvinas, Inc.
Leadership Changes
- Mark C. McKenna: Appointed Chairman of the Board in August 2023. Mr. McKenna previously served as Chairman, President, and CEO of Prometheus Biosciences, Inc.
- Jennifer Fox and William “BJ” Jones: Joined the Board of Directors in June 2023, bringing expertise in financial and commercial operations.
- Rebecca Dabora, Ph.D.: Appointed Chief Technical Officer in June 2023, with expertise in chemistry, manufacturing, and controls.
Competitor Profile
Market Insights and Dynamics
The global market for I&I diseases is substantial, with conditions like atopic dermatitis and asthma affecting millions worldwide. The demand for innovative therapies that offer improved efficacy and dosing regimens is high, presenting opportunities for companies like Apogee to capture market share.
Competitor Analysis
- Dupixent (Sanofi/Regeneron): A leading biologic therapy for atopic dermatitis and asthma, with significant market presence.
- Tralokinumab (Tezspire, AstraZeneca): An IL-13 inhibitor approved for asthma, representing competition in the IL-13 targeting space.
